Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database
Aims Sevoflurane is an ether‐based inhalational anaesthetic that induces and maintains general anaesthesia. Our study aimed to detect sevoflurane‐induced nephrogenic diabetes insipidus using data mining algorithms (DMAs) and molecular docking. The FAERS database was analysed using OpenVigil 2.1 for...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 2024-08, Vol.90 (8), p.1804-1810 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1810 |
|---|---|
| container_issue | 8 |
| container_start_page | 1804 |
| container_title | British journal of clinical pharmacology |
| container_volume | 90 |
| creator | Jacob, Akhil T. Kumar, Ankitha Hari Halivana, Gayethri Lukose, Lipin Nair, Gouri Subeesh, Viswam |
| description | Aims
Sevoflurane is an ether‐based inhalational anaesthetic that induces and maintains general anaesthesia. Our study aimed to detect sevoflurane‐induced nephrogenic diabetes insipidus using data mining algorithms (DMAs) and molecular docking. The FAERS database was analysed using OpenVigil 2.1 for disproportionality analysis.
Methods
We analysed FAERS data from 2004 to 2022 to determine the incidence of nephrogenic diabetes insipidus associated with sevoflurane. Reporting odds ratios (RORs) and proportional reporting ratios (PRRs) with 95% confidence intervals were calculated. We also used molecular docking with AutoDock Vina to examine sevoflurane's binding affinity to relevant receptors.
Results
A total of 554 nephrogenic diabetes insipidus cases were reported in FAERS, of which 2.5% (14 cases) were associated with sevoflurane. Positive signals were observed for sevoflurane with ROR of 76.012 (95% CI: 44.67–129.35) and PRR of 75.72 (χ2: 934.688). Of the 14 cases, 50% required hospitalization, 14% resulted in death, and the remaining cases were categorized as other outcomes. Molecular docking analysis showed that sevoflurane exhibited high binding affinity towards AQP2 (4NEF) and AVPR2 (6U1N) with docking scores of −4.9 and −5.3, respectively.
Conclusions
Sevoflurane use is significantly associated with the incidence of nephrogenic diabetes insipidus. Healthcare professionals should be cautious when using this medication and report any adverse events to regulatory agencies. Further research is needed to validate these findings and identify risk factors while performing statistical adjustments to prevent false‐positives. Clinical monitoring is crucial to validate potential adverse effects of sevoflurane. |
| doi_str_mv | 10.1111/bcp.15869 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2846925041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2846925041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3609-5f0c96ea33068f8755a40bc4b05aeda545c430f98c39e1b6c202f63c984b6fce3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi1ERaeFBS-AvIRFWjuO3WQ5nV5AqlTEZR059vHUKImDjzMoOx6BV-ir9UkwncIOb87C3_mOfv2EvObshOd32pnphMtaNc_Iigsli5KX8jlZMcFUIUvJD8kR4jfGuOBKviCH4kwK1YhyRe7PffCjC3HQyRt8-PlrO3sLllqPUwxTiMmHUfc-LVTnuaBHGhxF2AXXz1GPkHf8aGeTl0aY7mLYwuhNFugOEiD1I_rJ2xnpjH7c0nQH9OpiTdd2BxGBXu5gTPQTPN7K_58XTDBQq5PuNMJLcuB0j_DqaR6Tr1eXXzbvi5vb6w-b9U1hhGJNIR0zjQItcuba1WdS6op1puqY1GC1rKSpBHNNbUQDvFOmZKVTwjR11SlnQByTt3tvjv19Bkzt4NFA3-eIYca2rCvVlJJVPKPv9qiJATGCa6foBx2XlrP2TyNtbqR9bCSzb560czeA_Uf-rSADp3vgh-9h-b-pPd983Ct_A9Amm-Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2846925041</pqid></control><display><type>article</type><title>Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Jacob, Akhil T. ; Kumar, Ankitha Hari ; Halivana, Gayethri ; Lukose, Lipin ; Nair, Gouri ; Subeesh, Viswam</creator><creatorcontrib>Jacob, Akhil T. ; Kumar, Ankitha Hari ; Halivana, Gayethri ; Lukose, Lipin ; Nair, Gouri ; Subeesh, Viswam</creatorcontrib><description>Aims
Sevoflurane is an ether‐based inhalational anaesthetic that induces and maintains general anaesthesia. Our study aimed to detect sevoflurane‐induced nephrogenic diabetes insipidus using data mining algorithms (DMAs) and molecular docking. The FAERS database was analysed using OpenVigil 2.1 for disproportionality analysis.
Methods
We analysed FAERS data from 2004 to 2022 to determine the incidence of nephrogenic diabetes insipidus associated with sevoflurane. Reporting odds ratios (RORs) and proportional reporting ratios (PRRs) with 95% confidence intervals were calculated. We also used molecular docking with AutoDock Vina to examine sevoflurane's binding affinity to relevant receptors.
Results
A total of 554 nephrogenic diabetes insipidus cases were reported in FAERS, of which 2.5% (14 cases) were associated with sevoflurane. Positive signals were observed for sevoflurane with ROR of 76.012 (95% CI: 44.67–129.35) and PRR of 75.72 (χ2: 934.688). Of the 14 cases, 50% required hospitalization, 14% resulted in death, and the remaining cases were categorized as other outcomes. Molecular docking analysis showed that sevoflurane exhibited high binding affinity towards AQP2 (4NEF) and AVPR2 (6U1N) with docking scores of −4.9 and −5.3, respectively.
Conclusions
Sevoflurane use is significantly associated with the incidence of nephrogenic diabetes insipidus. Healthcare professionals should be cautious when using this medication and report any adverse events to regulatory agencies. Further research is needed to validate these findings and identify risk factors while performing statistical adjustments to prevent false‐positives. Clinical monitoring is crucial to validate potential adverse effects of sevoflurane.</description><identifier>ISSN: 0306-5251</identifier><identifier>ISSN: 1365-2125</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.15869</identifier><identifier>PMID: 37536932</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Adverse Drug Reaction Reporting Systems - statistics & numerical data ; Aged ; Anesthetics, Inhalation - adverse effects ; AQP2 ; AVPR2 ; Child ; Child, Preschool ; Computational Biology ; Data Mining ; Databases, Factual - statistics & numerical data ; Diabetes Insipidus, Nephrogenic - chemically induced ; Diabetes Insipidus, Nephrogenic - epidemiology ; FAERS ; Female ; Humans ; Incidence ; Infant ; Male ; Middle Aged ; Molecular Docking Simulation ; nephrogenic diabetes insipidus (NDI) ; sevoflurane ; Sevoflurane - adverse effects ; United States - epidemiology ; United States Food and Drug Administration ; Young Adult</subject><ispartof>British journal of clinical pharmacology, 2024-08, Vol.90 (8), p.1804-1810</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3609-5f0c96ea33068f8755a40bc4b05aeda545c430f98c39e1b6c202f63c984b6fce3</citedby><cites>FETCH-LOGICAL-c3609-5f0c96ea33068f8755a40bc4b05aeda545c430f98c39e1b6c202f63c984b6fce3</cites><orcidid>0000-0002-4086-4693 ; 0000-0002-1721-4553 ; 0009-0007-6070-6733 ; 0000-0003-2081-6827 ; 0000-0001-8409-3491 ; 0009-0002-3518-2417</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.15869$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.15869$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37536932$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacob, Akhil T.</creatorcontrib><creatorcontrib>Kumar, Ankitha Hari</creatorcontrib><creatorcontrib>Halivana, Gayethri</creatorcontrib><creatorcontrib>Lukose, Lipin</creatorcontrib><creatorcontrib>Nair, Gouri</creatorcontrib><creatorcontrib>Subeesh, Viswam</creatorcontrib><title>Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Aims
Sevoflurane is an ether‐based inhalational anaesthetic that induces and maintains general anaesthesia. Our study aimed to detect sevoflurane‐induced nephrogenic diabetes insipidus using data mining algorithms (DMAs) and molecular docking. The FAERS database was analysed using OpenVigil 2.1 for disproportionality analysis.
Methods
We analysed FAERS data from 2004 to 2022 to determine the incidence of nephrogenic diabetes insipidus associated with sevoflurane. Reporting odds ratios (RORs) and proportional reporting ratios (PRRs) with 95% confidence intervals were calculated. We also used molecular docking with AutoDock Vina to examine sevoflurane's binding affinity to relevant receptors.
Results
A total of 554 nephrogenic diabetes insipidus cases were reported in FAERS, of which 2.5% (14 cases) were associated with sevoflurane. Positive signals were observed for sevoflurane with ROR of 76.012 (95% CI: 44.67–129.35) and PRR of 75.72 (χ2: 934.688). Of the 14 cases, 50% required hospitalization, 14% resulted in death, and the remaining cases were categorized as other outcomes. Molecular docking analysis showed that sevoflurane exhibited high binding affinity towards AQP2 (4NEF) and AVPR2 (6U1N) with docking scores of −4.9 and −5.3, respectively.
Conclusions
Sevoflurane use is significantly associated with the incidence of nephrogenic diabetes insipidus. Healthcare professionals should be cautious when using this medication and report any adverse events to regulatory agencies. Further research is needed to validate these findings and identify risk factors while performing statistical adjustments to prevent false‐positives. Clinical monitoring is crucial to validate potential adverse effects of sevoflurane.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse Drug Reaction Reporting Systems - statistics & numerical data</subject><subject>Aged</subject><subject>Anesthetics, Inhalation - adverse effects</subject><subject>AQP2</subject><subject>AVPR2</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Computational Biology</subject><subject>Data Mining</subject><subject>Databases, Factual - statistics & numerical data</subject><subject>Diabetes Insipidus, Nephrogenic - chemically induced</subject><subject>Diabetes Insipidus, Nephrogenic - epidemiology</subject><subject>FAERS</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Docking Simulation</subject><subject>nephrogenic diabetes insipidus (NDI)</subject><subject>sevoflurane</subject><subject>Sevoflurane - adverse effects</subject><subject>United States - epidemiology</subject><subject>United States Food and Drug Administration</subject><subject>Young Adult</subject><issn>0306-5251</issn><issn>1365-2125</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi1ERaeFBS-AvIRFWjuO3WQ5nV5AqlTEZR059vHUKImDjzMoOx6BV-ir9UkwncIOb87C3_mOfv2EvObshOd32pnphMtaNc_Iigsli5KX8jlZMcFUIUvJD8kR4jfGuOBKviCH4kwK1YhyRe7PffCjC3HQyRt8-PlrO3sLllqPUwxTiMmHUfc-LVTnuaBHGhxF2AXXz1GPkHf8aGeTl0aY7mLYwuhNFugOEiD1I_rJ2xnpjH7c0nQH9OpiTdd2BxGBXu5gTPQTPN7K_58XTDBQq5PuNMJLcuB0j_DqaR6Tr1eXXzbvi5vb6w-b9U1hhGJNIR0zjQItcuba1WdS6op1puqY1GC1rKSpBHNNbUQDvFOmZKVTwjR11SlnQByTt3tvjv19Bkzt4NFA3-eIYca2rCvVlJJVPKPv9qiJATGCa6foBx2XlrP2TyNtbqR9bCSzb560czeA_Uf-rSADp3vgh-9h-b-pPd983Ct_A9Amm-Y</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Jacob, Akhil T.</creator><creator>Kumar, Ankitha Hari</creator><creator>Halivana, Gayethri</creator><creator>Lukose, Lipin</creator><creator>Nair, Gouri</creator><creator>Subeesh, Viswam</creator><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4086-4693</orcidid><orcidid>https://orcid.org/0000-0002-1721-4553</orcidid><orcidid>https://orcid.org/0009-0007-6070-6733</orcidid><orcidid>https://orcid.org/0000-0003-2081-6827</orcidid><orcidid>https://orcid.org/0000-0001-8409-3491</orcidid><orcidid>https://orcid.org/0009-0002-3518-2417</orcidid></search><sort><creationdate>202408</creationdate><title>Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database</title><author>Jacob, Akhil T. ; Kumar, Ankitha Hari ; Halivana, Gayethri ; Lukose, Lipin ; Nair, Gouri ; Subeesh, Viswam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3609-5f0c96ea33068f8755a40bc4b05aeda545c430f98c39e1b6c202f63c984b6fce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse Drug Reaction Reporting Systems - statistics & numerical data</topic><topic>Aged</topic><topic>Anesthetics, Inhalation - adverse effects</topic><topic>AQP2</topic><topic>AVPR2</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Computational Biology</topic><topic>Data Mining</topic><topic>Databases, Factual - statistics & numerical data</topic><topic>Diabetes Insipidus, Nephrogenic - chemically induced</topic><topic>Diabetes Insipidus, Nephrogenic - epidemiology</topic><topic>FAERS</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Docking Simulation</topic><topic>nephrogenic diabetes insipidus (NDI)</topic><topic>sevoflurane</topic><topic>Sevoflurane - adverse effects</topic><topic>United States - epidemiology</topic><topic>United States Food and Drug Administration</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacob, Akhil T.</creatorcontrib><creatorcontrib>Kumar, Ankitha Hari</creatorcontrib><creatorcontrib>Halivana, Gayethri</creatorcontrib><creatorcontrib>Lukose, Lipin</creatorcontrib><creatorcontrib>Nair, Gouri</creatorcontrib><creatorcontrib>Subeesh, Viswam</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacob, Akhil T.</au><au>Kumar, Ankitha Hari</au><au>Halivana, Gayethri</au><au>Lukose, Lipin</au><au>Nair, Gouri</au><au>Subeesh, Viswam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2024-08</date><risdate>2024</risdate><volume>90</volume><issue>8</issue><spage>1804</spage><epage>1810</epage><pages>1804-1810</pages><issn>0306-5251</issn><issn>1365-2125</issn><eissn>1365-2125</eissn><abstract>Aims
Sevoflurane is an ether‐based inhalational anaesthetic that induces and maintains general anaesthesia. Our study aimed to detect sevoflurane‐induced nephrogenic diabetes insipidus using data mining algorithms (DMAs) and molecular docking. The FAERS database was analysed using OpenVigil 2.1 for disproportionality analysis.
Methods
We analysed FAERS data from 2004 to 2022 to determine the incidence of nephrogenic diabetes insipidus associated with sevoflurane. Reporting odds ratios (RORs) and proportional reporting ratios (PRRs) with 95% confidence intervals were calculated. We also used molecular docking with AutoDock Vina to examine sevoflurane's binding affinity to relevant receptors.
Results
A total of 554 nephrogenic diabetes insipidus cases were reported in FAERS, of which 2.5% (14 cases) were associated with sevoflurane. Positive signals were observed for sevoflurane with ROR of 76.012 (95% CI: 44.67–129.35) and PRR of 75.72 (χ2: 934.688). Of the 14 cases, 50% required hospitalization, 14% resulted in death, and the remaining cases were categorized as other outcomes. Molecular docking analysis showed that sevoflurane exhibited high binding affinity towards AQP2 (4NEF) and AVPR2 (6U1N) with docking scores of −4.9 and −5.3, respectively.
Conclusions
Sevoflurane use is significantly associated with the incidence of nephrogenic diabetes insipidus. Healthcare professionals should be cautious when using this medication and report any adverse events to regulatory agencies. Further research is needed to validate these findings and identify risk factors while performing statistical adjustments to prevent false‐positives. Clinical monitoring is crucial to validate potential adverse effects of sevoflurane.</abstract><cop>England</cop><pmid>37536932</pmid><doi>10.1111/bcp.15869</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4086-4693</orcidid><orcidid>https://orcid.org/0000-0002-1721-4553</orcidid><orcidid>https://orcid.org/0009-0007-6070-6733</orcidid><orcidid>https://orcid.org/0000-0003-2081-6827</orcidid><orcidid>https://orcid.org/0000-0001-8409-3491</orcidid><orcidid>https://orcid.org/0009-0002-3518-2417</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2024-08, Vol.90 (8), p.1804-1810 |
| issn | 0306-5251 1365-2125 1365-2125 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2846925041 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult Adverse Drug Reaction Reporting Systems - statistics & numerical data Aged Anesthetics, Inhalation - adverse effects AQP2 AVPR2 Child Child, Preschool Computational Biology Data Mining Databases, Factual - statistics & numerical data Diabetes Insipidus, Nephrogenic - chemically induced Diabetes Insipidus, Nephrogenic - epidemiology FAERS Female Humans Incidence Infant Male Middle Aged Molecular Docking Simulation nephrogenic diabetes insipidus (NDI) sevoflurane Sevoflurane - adverse effects United States - epidemiology United States Food and Drug Administration Young Adult |
| title | Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T10%3A21%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bioinformatics%E2%80%90guided%20disproportionality%20analysis%20of%20sevoflurane%E2%80%90induced%20nephrogenic%20diabetes%20insipidus%20using%20the%20FDA%20Adverse%20Event%20Reporting%20System%20database&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Jacob,%20Akhil%20T.&rft.date=2024-08&rft.volume=90&rft.issue=8&rft.spage=1804&rft.epage=1810&rft.pages=1804-1810&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.15869&rft_dat=%3Cproquest_cross%3E2846925041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2846925041&rft_id=info:pmid/37536932&rfr_iscdi=true |